Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Slides:

Advertisements

Similar presentations

Abrar M. Radwan Saleh Dr. Adham Abo-Taha An-Najah National University College of Pharmacy Pharmacy Program: Pharm D.

Advertisements

My Treatment Approach to Rheumatoid Arthritis

Figure 1 Lymphocytes during the disease

Figure 1 Role of innate lymphoid cells (ILCs) in steady state,

of different experimental arthritis models

Figure 1 Historical evolution of the clinical classification and

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Enthesitis versus synovitis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Structure of TNF antagonists

Figure 1 Induction of immune tolerance

Figure 3 Methods to detect trough levels of therapeutic antibodies

Figure 2 Assays for detecting antidrug antibodies to TNF inhibitors

My Treatment Approach to Rheumatoid Arthritis

Figure 4 Simplified T cell and antigen presenting

Figure 3 Proposed mechanisms underlying the links

Figure 2 Heat map of targeted therapies in autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Main functions of IL-1

Figure 4 Involvement of SEMA4D in the pathogenesis

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

The Inflammasomes in Autoinflammatory Diseases with Skin Involvement

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 GlyR antibody binding

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases.

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 7 Defects in apoptosis

Figure 1 Location of HLA variants known to be associated

Figure 3 Defects in the T cell receptor signalling pathway

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Approaches to targeting inhibitory immune receptors

Figure 1 Pharmacodynamics of methotrexate in RA

Figure 1 Activation and signalling of IL-1

Figure 2 Overlap of associated loci among five rheumatic diseases

Figure 2 Interaction effects between heterozygous HLA‑DRB1

Nat. Rev. Rheumatol. doi: /nrrheum

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

Figure 3 Statistical approaches for the analysis of metabolomic data

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Effect of sialylated glycoforms on IgG activity

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Research advances in osteoarthritis management

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Reproductive health in patients with rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Figure 1 Extrinsic and intrinsic pathways of apoptosis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The role of macrophages in RA

Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.

Nat. Rev. Rheumatol. doi: /nrrheum

Changes over time of the daily prednisone dose in patients that responded to anakinra. Changes over time of the daily prednisone dose in patients that.

Anti-CarALB antibody prevalence and levels in RA and other CTD

Presentation transcript:

Figure 3 Strategies to achieve therapeutic inhibition of IL-1 Figure 3 | Strategies to achieve therapeutic inhibition of IL-1. Structural, pharmacological and disease characteristics of current interleukin IL-1 inhibitors. Rilonacept has one extracellular domain of IL-1 receptor type 1 (IL-1R1) and one of IL-1 receptor accessory protein (IL-1RAcP) bound to the Fc portion of IgG. AOSD, adult onset Still disease; CAPS, cryopyrin-associated periodic syndrome; CPPD, calcium pyrophosphate disease; CP, calcifying periarthritis; CVD, cardiovascular disease; IL-1Ra, IL-1 receptor antagonist; mAb, monoclonal antibody; RA, rheumatoid arthritis; sJIA, systemic juvenile idiopathic arthritis. Schett, G. et al. (2015) Interleukin‑1 function and role in rheumatic disease Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.166